Dr. Sara Sambandham, MD

Dr. Sambandham practices at Wellstar Kennestone Regional Medical Center in Marietta, Georgia, part of Wellstar Health System.

Dr. Sambandham's NPI, 1790940831, was assigned on July 28, 2008. Dr. Sambandham holds Georgia license 064964.

Dr. Sambandham's primary practice is Wellstar Kennestone Regional Medical Center, at 677 Church Street, Marietta, GA 30060 in Cobb County. The practice phone is (770) 793-5000.

Dr. Sambandham's primary practice is Wellstar Kennestone Regional Medical Center in Marietta, Georgia, part of Wellstar Health System. Dr. Sambandham is also affiliated with Wellstar Cobb Medical Center. The medical group on file is Wellstar Medical Group. Dmand AI also links Dr. Sambandham to 1 more hospital, 1 home health agency and 1 medical group, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Sambandham practices, 4 sites in all. Vendor and product names are available with a free account.

Hospitalist is Dr. Sambandham's primary specialty in the NPI Registry, under taxonomy code 208M00000X. Dmand AI has Dr. Sambandham's licenses on file in 2 states: Georgia and North Carolina.

CMS data shows 1,021 Medicare services from Dr. Sambandham across 5 procedure codes in 2024, for 385 Medicare patients. Medicare paid $87,539 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 385 Medicare patients who saw Dr. Sambandham in 2024. The largest group is 75 to 84, with 154 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 18% are also on Medicaid. Their average risk score is 2.31, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Sambandham's median patient age at 76, with 58% women.

In 2024, Dr. Sambandham wrote 269 Medicare Part D claims for 107 patients. 84% of them were for generic drugs. CMS names the drug for 101 of them, across 7 drugs with 11 or more claims each, at $2,070 in total drug cost. In 2023, CMS named 110 claims across 7 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 94 out of 100 for Dr. Sambandham for performance year 2024, reported through an alternative payment model (APM). Dr. Sambandham accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

CMS Open Payments shows 77 general payments to Dr. Sambandham from 23 drug and device companies from 2016 to 2025. Food and beverage make up the largest share, 100% of the total. Janssen Pharmaceuticals, Inc paid the most, $384.